RespireRx Pharmaceuticals Inc (fka RSPI)

[ombowstring]

Neuro, I'd be very interested in your speculations re the questions you brought up in your post #14167:

Is the RD indication for real, with real potential value? Is the trial design one which is likely to work, and if it doesn't, what then? To what degree are Ampakines as a class viewed negatively by the FDA--or not? What will Schering-Plough do? What are the industry trends for partnerships and indications, and what do they augur for Cortex, if anything? How much clout does R&R have in trying to force a sale on the cheap?

One more question I have for you -- What do you think the level of partnership interest in Cortex is among bigger pharmaceutical companies at this time and if the RD and AD trials yield good results?

P.S. Let's hope this sudden burst of acrimony between you and gfp blows over quickly and is soon forgotten.